FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034921189> ?p ?o ?g. }

• W2034921189 endingPage "28756" @default.
• W2034921189 startingPage "28749" @default.
• W2034921189 abstract "In contrast to HLA-B*2705, B*2709 is weakly or not associated to ankylosing spondylitis. Both allotypes differ by a single D116H change. We compared the B*2705- and B*2709-bound peptide repertoires by mass spectrometry to quantify the effect of B*2709 polymorphism on peptide specificity. In addition, shared and differentially bound ligands were sequenced to define the structural features of the various peptide subsets. B*2705 shared 79% of its peptide repertoire with B*2709. Shared ligands accounted for 88% of the B*2709-bound repertoire. All B*2705 ligands not bound to B*2709 had C-terminal basic or Tyr residues. Most B*2709-bound peptides had C-terminal aliphatic and Phe residues, but two showed C-terminal Arg or Tyr. The B*2709-bound repertoire included 12% of peptides not found in B*2705. These had aliphatic C-terminal residues, which are also favored in B*2705. However, these peptides bound weakly B*2705 in vitro, indicating distinct contribution of secondary anchor residues in both subtypes. Differences in peptide binding did not affect the ratio of native to β2-microglobulin-free HLA-B27 heavy chain at the cell surface. Our results suggest that weaker association of B*2709 with ankylosing spondylitis is based on differential binding of a limited subset of natural ligands by this allotype. In contrast to HLA-B*2705, B*2709 is weakly or not associated to ankylosing spondylitis. Both allotypes differ by a single D116H change. We compared the B*2705- and B*2709-bound peptide repertoires by mass spectrometry to quantify the effect of B*2709 polymorphism on peptide specificity. In addition, shared and differentially bound ligands were sequenced to define the structural features of the various peptide subsets. B*2705 shared 79% of its peptide repertoire with B*2709. Shared ligands accounted for 88% of the B*2709-bound repertoire. All B*2705 ligands not bound to B*2709 had C-terminal basic or Tyr residues. Most B*2709-bound peptides had C-terminal aliphatic and Phe residues, but two showed C-terminal Arg or Tyr. The B*2709-bound repertoire included 12% of peptides not found in B*2705. These had aliphatic C-terminal residues, which are also favored in B*2705. However, these peptides bound weakly B*2705 in vitro, indicating distinct contribution of secondary anchor residues in both subtypes. Differences in peptide binding did not affect the ratio of native to β2-microglobulin-free HLA-B27 heavy chain at the cell surface. Our results suggest that weaker association of B*2709 with ankylosing spondylitis is based on differential binding of a limited subset of natural ligands by this allotype. ankylosing spondylitis spondyloarthropathies monoclonal antibody high pressure liquid chromatography matrix-assisted laser desorption/ionization time-of-flight mass spectrometry cytolytic T lymphocytes The association of HLA-B27 with ankylosing spondylitis (AS)1 and other spondyloarthropathies (Spa) ranks among the strongest of any MHC antigen with a human disease, although the mechanism of this association remains unknown. The differential linkage of HLA-B27 subtypes to AS revealed by population studies is expected to provide unique insight into the pathogenetic role of HLA-B27. Whereas B*2705, B*2702, B*2704, and B*2707 are all associated to AS (1Gonzalez-Roces S. Alvarez M.V. Gonzalez S. Dieye A. Makni H. Woodfield D.G. Housan L. Konenkov V. Abbadi M.C. Grunnet N. Coto E. Lopez-Larrea C. Tissue Antigens. 1997; 49: 116-123Crossref PubMed Scopus (209) Google Scholar), B*2706 and B*2709 are weakly or not associated to this disease (2Lopez-Larrea C. Sujirachato K. Mehra N.K. Chiewsilp P. Isarangkura D. Kanga U. Dominguez O. Coto E. Peña M. Setien F. Gonzalez-Roces S. Tissue Antigens. 1995; 45: 169-176Crossref PubMed Scopus (241) Google Scholar, 3Nasution A.R. Mardjuadi A. Kunmartini S. Suryadhana N.G. Setyohadi B. Sudarsono D. Lardy N.M. Feltkamp T.E. J. Rheumatol. 1997; 24: 1111-1114PubMed Google Scholar, 4Ren E.C. Koh W.H. Sim D. Boey M.L. Wee G.B. Chan S.H. Tissue Antigens. 1997; 49: 67-69Crossref PubMed Scopus (86) Google Scholar, 5D'Amato M. Fiorillo M.T. Carcassi C. Mathieu A. Zuccarelli A. Bitti P.P. Tosi R. Sorrentino R. Eur. J. Immunol. 1995; 25: 3199-3201Crossref PubMed Scopus (186) Google Scholar). In particular, B*2709 is not associated to AS in Sardinia, the only population where it has been found at significant frequency (5D'Amato M. Fiorillo M.T. Carcassi C. Mathieu A. Zuccarelli A. Bitti P.P. Tosi R. Sorrentino R. Eur. J. Immunol. 1995; 25: 3199-3201Crossref PubMed Scopus (186) Google Scholar). In continental Italy, where this allotype is found at much lower frequency (about 3% of HLA-B27 individuals), a patient with undifferentiated Spa without axial involvement was initially reported (6Olivieri I. Padula A. Cianco G. Moro L. Durante E. Guadiano C. Masciandaro S. Pozzi S. Ferrara G.B. Ann. Rheum. Dis. 2000; 59: 654-655Crossref PubMed Google Scholar). More recently, 2 of 47 individuals with Spa in southern continental Italy were found to be B*2709. Again, both patients showed undifferentiated Spa without axial involvement (7Olivieri I. Ciancio G. Padula A. Gaudiano C. Masciandaro S. Moro L. Durante E. Pozzi S. Ferrara G.B. Arthritis Rheum. 2002; 46: 553-554Crossref PubMed Scopus (25) Google Scholar). In an independent study (8Marchionni L. Modena V. Roggero R. Curtoni E.S. The polymorphism of HLA-B27 and the seronegative spondyloarthropathies in the Italian population.13th European Histocompatibility Conference. European Federation for Immunogenetics, Crete1999Google Scholar) a B*2709 individual with sacroiliitis and oligoarthritis was reported. The finding of a few individuals with Spa, but not AS, supports a lower association of B*2709 with this disease, while suggesting some involvement of this subtype with related forms of arthritis. B*2709 differs from B*2705 by a single amino acid substitution, D116H (9Del Porto P. D'Amato M. Fiorillo M.T. Tuosto L. Piccolella E. Sorrentino R. J. Immunol. 1994; 153: 3093-3100PubMed Google Scholar). This change, which is unique among known HLA-B27 subtypes, was reported to restrict peptide binding specificity to ligands with C-terminal nonpolar residues (10Fiorillo M.T. Meadows L. D'Amato M. Shabanowitz J. Hunt D.F. Apella E. Sorrentino R. Eur. J. Immunol. 1997; 27: 368-373Crossref PubMed Scopus (98) Google Scholar). This is in contrast with B*2705, which binds peptides with C-terminal basic, aliphatic, and aromatic residues (11Jardetzky T.S. Lane W.S. Robinson R.A. Madden D.R. Wiley D.C. Nature. 1991; 353: 326-329Crossref PubMed Scopus (735) Google Scholar). Previous studies did not address the effects of B*2709 polymorphism on other anchor positions of natural ligands or, more importantly, the overall effect of altered binding specificity on the constitutive peptide repertoire. In the present study we carried out a systematic comparison of the B*2705- and B*2709-bound peptide repertoires to determine the percentage of natural ligands shared by both allotypes. In addition, we sequenced a large number of peptides either common to both subtypes or selectively presented by one of them, to identify the structural features determining differential binding to both subtypes. Finally, we compared the expression of β2-microglobulin-free B*2705 and B*2709 heavy chains to test whether differential peptide binding might result in altered cell surface stability HLA B*2709 genomic DNA was obtained from a B*2705 genomic construct (12Calvo V. Rojo S. Lopez D. Galocha B. Lopez de Castro J.A. J. Immunol. 1990; 144: 4038-4045PubMed Google Scholar), substituting theXcmI-BssHII fragment (nucleotides 360–610) by the same fragment containing the 418G → C mutation (resulting in the D116H) obtained from a cDNA coding for B*2709 (a kind gift from R. Sorrentino). The resulting genomic construct was thoroughly sequenced to ensure that it contained only the desired mutation. HMy2.C1R (C1R) is a human lymphoid cell line with low expression of its endogenous class I antigens (13Storkus W.J. Howell D.N. Salter R.D. Dawson J.R. Cresswell P. J. Immunol. 1987; 138: 1657-1659PubMed Google Scholar, 14Zemmour J. Little A.M. Schendel D.J. Parham P. J. Immunol. 1992; 148: 1941-1948PubMed Google Scholar). B*2705-C1R transfectant cells were described elsewhere (12Calvo V. Rojo S. Lopez D. Galocha B. Lopez de Castro J.A. J. Immunol. 1990; 144: 4038-4045PubMed Google Scholar). The B*2709-C1R transfectant cell line was made as described (12Calvo V. Rojo S. Lopez D. Galocha B. Lopez de Castro J.A. J. Immunol. 1990; 144: 4038-4045PubMed Google Scholar) using the B*2709 gene. For some experiments a C1R cell line transfected with B*2709 cDNA was also used (15Garcia-Peydro M. Marti M. Lopez de Castro J.A. J. Immunol. 1999; 163: 2299-2305PubMed Google Scholar). C1R cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 7.5% fetal bovine serum or, for flow cytometry, in RPMI 1640 medium supplemented with 10% fetal bovine serum (all from Invitrogen). RMA-S is a TAP-deficient murine cell line (16Ljunggren H.G. Karre K. J. Exp. Med. 1985; 162: 1745-1759Crossref PubMed Scopus (647) Google Scholar, 17Townsend A. Ohlen C. Bastin J. Ljunggren H.G. Foster L. Karre K. Nature. 1989; 340: 443-448Crossref PubMed Scopus (884) Google Scholar). RMA-S transfectant cells expressing B*2705 and human β2-microglobulin have been previously described (18Villadangos J.A. Galocha B. Lopez de Castro J.A. J. Immunol. 1994; 152: 2317-2323PubMed Google Scholar). These cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum. The mAbs used in this study were W6/32 (IgG2a, specific for a monomorphic HLA-A, B, C determinant) (19Barnstable C.J. Bodmer W.F. Brown G. Galfre G. Milstein C. Williams A.F. Ziegler A. Cell. 1978; 14: 9-20Abstract Full Text PDF PubMed Scopus (1600) Google Scholar), ME1 (IgG1, specific for HLA-B27, B7, Bw22) (20Ellis S.A. Taylor C. McMichael A. Hum. Immunol. 1982; 5: 49-59Crossref PubMed Scopus (201) Google Scholar), BBM.1 (IgG2b, specific for human β2-microglobulin) (21Brodsky F.M. Bodmer W.F. Parham P. Eur. J. Immunol. 1979; 9: 536-545Crossref PubMed Scopus (250) Google Scholar, 22Parham P. Androlewicz M.J. Holmes N.J. Rothenberg B.E. J. Biol. Chem. 1983; 258: 6179-6186Abstract Full Text PDF PubMed Google Scholar), and HC10 (IgG2a, specific for denatured and other forms of HLA class I heavy chain not associated to β2-microglobulin) (23Stam N.J. Spits H. Ploegh H.L. J. Immunol. 1986; 137: 2299-2306PubMed Google Scholar). About 6 × 104untransfected, B*2705- or B*2709-C1R transfectant cells were washed twice in 200 μl of phosphate-buffered saline and resuspended in 50 μl of undiluted mAb supernatant. After incubating for 30 min, cells were washed two times in 200 μl of phosphate-buffered saline and resuspended in 50 μl of fluorescein isothiocyanate-conjugated anti-mouse IgG rabbit antiserum (Calbiochem-Novabiochem GMBH, Schwalbach, Germany), incubated for 30 min, and washed two times in 200 μl of phosphate-buffered saline. All operations were done at 4 °C. Flow cytometry was carried out in an Epics Profile XL instrument (Coulter Electronics Inc., Hialeah, FL). Isolation of HLA-B27-bound peptides from about 1010 HLA-B27 transfectant C1R cells was carried out as previously described (24Paradela A. Garcia-Peydro M. Vazquez J. Rognan D. Lopez de Castro J.A. J. Immunol. 1998; 161: 5481-5490PubMed Google Scholar). Briefly, cells were lysed in 1% Nonidet P-40 in the presence of a mixture of protease inhibitors. After centrifugation, cell lysates were subjected to affinity chromatography using the W6/32 mAb. HLA-B27-bound peptides were eluted with 0.1% aqueous trifluoroacetic acid at room temperature, filtered trough Centricon 3 (Amicon, Beverly, MA), and concentrated for HPLC fractionation. This was conducted in a Waters Alliance system (Waters, Milford, MA) using a Vydac 218TP52 column (Vydac, Hesperia, CA) at a flow rate of 100 μl/min, exactly as described (25Paradela A. Alvarez I. Garcia-Peydro M. Sesma L. Ramos M. Vazquez J. Lopez de Castro J.A. J. Immunol. 2000; 164: 329-337Crossref PubMed Scopus (37) Google Scholar). Fractions of 50 μl were collected. The peptide composition of HPLC fractions was analyzed by MALDI-TOF MS using a calibrated Kompact Probe instrument (Kratos-Schimadzu) operating in the positive linear mode, as previously described (25Paradela A. Alvarez I. Garcia-Peydro M. Sesma L. Ramos M. Vazquez J. Lopez de Castro J.A. J. Immunol. 2000; 164: 329-337Crossref PubMed Scopus (37) Google Scholar). Dried fractions were resuspended in 5 μl of methanol/water (1:1) containing 0.1% formic acid, and 0.5-μl aliquots of the sample were deposited onto the stainless steel MALDI probe and allowed to dry at room temperature. Then 0.5 μl of matrix solution (saturated α-cyano-4-hydroxycinnamic acid in 33% aqueous acetonitrile and 0.1% trifluoroacetic acid) was added and again allowed to dry at room temperature. Peptide sequencing was carried out by quadrupole ion trap nanoelectrospray MS/MS in an LCQ instrument (Finnigan ThermoQuest, San Jose, CA), exactly as detailed elsewhere (26Yague J. Vazquez J. Lopez de Castro J.A. Tissue Antigens. 1998; 52: 416-421Crossref PubMed Scopus (21) Google Scholar, 27Marina A. Garcia M.A. Albar J.P. Yague J. Lopez de Castro J.A. Vazquez J. J. Mass Spectrom. 1999; 34: 17-27Crossref PubMed Scopus (58) Google Scholar). One peptide was sequenced by MALDI-TOF/TOF using the Applied Biosystems 4700 Proteomics Analyser with TOF/TOFTM optics. The corresponding HPLC fraction was dried and redissolved in methanol/formic acid/water as above. A 1-μl aliquot was mixed with 1 μl of matrix (α-cyano-4-hydroxycinnamic acid: 2.5 mg/ml in acetonitrile/0.1% trifluoroacetic acid/water, 1:1). Full scan MS was carried out by MALDI-TOF, and the selected ion peak was subjected to MS/MS. Assignment of the isobaric Ile/Leu or Lys/Gln residues was done on the basis of unambiguous matching with known sequences in the data base. In one case (TRIPKIQKL), assignment of Lys8 was not possible by this procedure, and the residue was assigned on the basis of identity of retention time in HPLC of the corresponding synthetic peptide, but not of the peptide with Gln8, with the natural ligand. These were synthesized using standard Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry, and purified by HPLC. The correct molecular mass of purified peptides was established by MALDI-TOF MS, and their correct composition and quantification was done by amino acid analysis after hydrolysis in 6m HCL using a 6300 Amino Acid Analyzer (Beckman Coulter, Palo Alto, CA). The epitope stabilization assay used to measure peptide binding was performed as described (28Galocha B. Lamas J.R. Villadangos J.A. Albar J.P. Lopez de Castro J.A. Tissue Antigens. 1996; 48: 509-518Crossref PubMed Scopus (37) Google Scholar) with minor modifications. Briefly, B*2705 RMA-S transfectants were incubated at 26 °C for 22 h in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum. These were then washed three times in AIM-V serum-free medium (Invitrogen), incubated for 1 h at 26 °C with various peptide concentrations in the same medium, transferred to 37 °C, and collected for flow cytometry after 4 h. HLA-B27 expression was measured using 50 μl of hybridoma culture supernatant containing the mAb ME1. Binding of the RRYQKSTEL peptide, used as positive control, was expressed as C50, which is the molar concentration of the peptide at 50% of the maximum fluorescence obtained at the concentration range 100–0.01 μm. Binding of other peptides was assessed as the concentration of peptide required to obtain the fluorescence value at the C50 of the control peptide. This was designated as EC50. The B*2705- and B*2709-bound peptide pools were isolated from the corresponding C1R transfectant cells after immunoprecipitation of HLA-B27 and acid extraction. The peptide pools were fractionated by HPLC under identical conditions, and the peptide composition of individual fractions was analyzed by MALDI-TOF MS. The spectrum of each HPLC fraction from one subtype was compared with the correlative, previous and following fractions from the other subtype. In this comparison only ion peaks showing 5% or more of the maximum intensity in the corresponding HPLC fraction of at least one subtype were taken into account. Ion peaks with the same (± 1) mass-to-charge ratio (m/z) and retention times were assigned as identical ligands in both subtypes. Although because of the complexity of the peptide mixture analyzed this is not always the case, it is reasonable to assume that the overwhelming majority of peptides with the same molecular mass and retention time from these peptide pools are identical. This was confirmed by sequencing such peptides from both subtypes in multiple instances. Ion peaks detected from only one subtype in two independent preparations were assigned as peptides differentially bound to that subtype. In a number of cases a prominent ion peak in one subtype had a much smaller counterpart in the other subtype. In all these cases the peptides were assigned as shared ligands. When the prominent ion peak showed >50% of the maximal intensity in the MALDI-TOF MS spectrum, and the intensity of its counterpart in the other subtype was at least 10-fold lower in two independent preparations, the corresponding peptide was assigned as a quantitative difference. This type of assignment must be considered with caution because the ion intensity of a given peptide in complex mixtures may have significant variations and is not an accurate indication of peptide amount. However, with the conservative criteria adopted concerning signal intensity differences and reproducibility we attempted to compensate in part for this limitation. A total of 1221 and 1094 molecular species were compared from the B*2705- and B*2709-bound peptide pools, respectively (TableI). Of these, 965 ion peaks were detected in both subtypes, 256 only in B*2705, and 129 only in B*2709. Thus, the B*2705-bound peptide pool includes 21% of peptides not found in B*2709. Conversely, the B*2709-bound peptide pool includes about 12% of peptides absent from B*2705. The mean molecular mass of B*2705 and B*2709 ligands was very similar, although peptides differentially bound to B*2705 had a mean molecular mass 24 Da higher (Fig.1). Within the shared ligands 143 and 165 ion peaks from B*2705 or B*2709, respectively, showed sufficient intensity to fulfill the criteria for assessing quantitative differences. Of these, 15 molecular species (10%) were assigned as quantitative differences predominant in B*2705, and 27 (16%) predominant in B*2709.Table IComparison of B*2705- and B*2709-bound peptide repertoiresB*2705 ligandsB*2709 ligandsTotalSharedSpecificTotalSharedSpecific1221965 (79%)256 (21%)1094965 (88%)129 (12%)Quantitative differences between B*2705 and B*2709In B*2705In B*2709Predominant/counted (%)15/143 (10)27/165 (16) Open table in a new tab These results indicate that the single amino acid change distinguishing B*2709 from B*2705 allows binding of 79% of the natural B*2705-bound ligands, abrogates binding of the remaining 21%, and substantially decreases the amount of bound peptide of at least 10% of shared ligands. Moreover, B*2709 polymorphism confers to this subtype distinct binding capacity, so that 12% of the peptide repertoire from this subtype is absent from B*2705, and at least 16% of shared ligands are significantly more abundant in B*2709. A total of 64 peptides were sequenced, mainly by nanoelectrospray MS/MS, from the B*2705- and/or B*2709-bound peptide pools. They included 32 shared ligands, of which 7 were quantitative differences predominant in B*2705 (2Lopez-Larrea C. Sujirachato K. Mehra N.K. Chiewsilp P. Isarangkura D. Kanga U. Dominguez O. Coto E. Peña M. Setien F. Gonzalez-Roces S. Tissue Antigens. 1995; 45: 169-176Crossref PubMed Scopus (241) Google Scholar) or B*2709 (5D'Amato M. Fiorillo M.T. Carcassi C. Mathieu A. Zuccarelli A. Bitti P.P. Tosi R. Sorrentino R. Eur. J. Immunol. 1995; 25: 3199-3201Crossref PubMed Scopus (186) Google Scholar), 23 ligands found only in B*2705, and 9 ligands found only in B*2709 (Fig.2). All the peptides found only in B*2705 had C-terminal basic (Arg, Lys) or Tyr residues, whereas shared ligands, except quantitative differences, had C-terminal nonpolar residues, including aliphatic ones (Ala, Leu, Val, Met) or Phe. These results confirm previous studies (10Fiorillo M.T. Meadows L. D'Amato M. Shabanowitz J. Hunt D.F. Apella E. Sorrentino R. Eur. J. Immunol. 1997; 27: 368-373Crossref PubMed Scopus (98) Google Scholar) showing that B*2709 polymorphism restricts binding to peptides with C-terminal hydrophobic residues. In addition, two novel findings arise from our results. First, this restriction was not absolute because two peptides with C-terminal Tyr and Arg, respectively, were found as natural ligands of B*2709, albeit in much lower amount than in B*2705. The identity of the peptide with a C-terminal Tyr in B*2709 was formally confirmed by MS/MS sequencing (Fig. 2). Second, a number of peptides with C-terminal aliphatic residues (Leu, Ile, Val, Cys) were found only or predominantly in B*2709, indicating that, although these residues are also favored in B*2705, some such peptides do not bind or bind inefficiently to this subtype in vivo. However, no obvious differential usage of particular residues was observed at positions other than the C-terminal one between peptides found only or predominantly in B*2705, and those differentially bound to B*2709. To confirm that B*2709 ligands not found in B*2705 were indeed poor binders to this allotype, three such peptides were tested for binding to B*2705 in an epitope stabilization assay using RMA-S transfectant cells (Fig. 3). All B*2709 ligands tested bound B*2705 with moderate efficiency (EC50 ≥ 17 μm) and significantly more weakly than a B*2705 ligand used as positive control (C50, 3 μm). These results explain that, despite having major anchor residues suitable for B*2705, some B*2709 ligands are not found in B*2705. We tested the possibility that alterations in the nature and affinity of the constitutive peptide repertoire induced by B*2709 polymorphism might change the expression level of free HLA-B27 heavy chain on the cell surface, as recently observed with the C67S mutation on B*2705 (29Alvarez I. Martı́ M. Vazquez J. Camafeita E. Ogueta S. Lopez de Castro J.A. J. Biol. Chem. 2001; 276: 48740-48747Abstract Full Text Full Text PDF PubMed Scopus (37) Google Scholar). Thus, HLA-B27 expression was analyzed on B*2705- and B*2709-C1R transfectant cells by flow cytometry with mAbs ME1, W6/32, and BBM.1, all reacting with the native molecule and with HC10, which reacts with β2-microglobulin-free HLA class I heavy chains. With all mAbs the surface expression of either native or β2-microglobulin-free B*2705 and B*2709 molecules was very similar (Fig. 4). The ratio of ME1- to HC10-associated fluorescence was about 18: 1 and 21:1 for B*2705 and B*2709, respectively (Table II), suggesting that about 5% of the molecules of each subtype were expressed at the cell surface as β2-microglobulin-free heavy chains.Table IIExpression of B*2705 and B*2709 on the surface of C1R transfectant cellsmAbMean fluorescence ± S.D.C1RB*2705-C1RB*2709-C1RME10.6 ± 0.132.3 ± 8.540.3 ± 8.6W6/327.2 ± 2.648.7 ± 19.248.1 ± 21.6BBM.111.8 ± 7.555.2 ± 14.057.6 ± 16.0HC101.3 ± 0.43.1 ± 0.93.2 ± 0.5 Open table in a new tab The HLA-B27 prototype, B*2705, binds with few exceptions (29Alvarez I. Martı́ M. Vazquez J. Camafeita E. Ogueta S. Lopez de Castro J.A. J. Biol. Chem. 2001; 276: 48740-48747Abstract Full Text Full Text PDF PubMed Scopus (37) Google Scholar) peptides with an Arg2 and C-terminal basic, aliphatic, or aromatic residues (11Jardetzky T.S. Lane W.S. Robinson R.A. Madden D.R. Wiley D.C. Nature. 1991; 353: 326-329Crossref PubMed Scopus (735) Google Scholar). Whereas Arg2 is a major motif shared with other HLA-B27 subtypes, these differ among each other in the nature of accepted C-terminal residues. Because B*2702, which like B*2705 is associated to AS presents only peptides with C-terminal aliphatic or aromatic residues (30Rotzschke O. Falk K. Stevanovic S. Gnau V. Jung G. Rammensee H.G. Immunogenetics. 1994; 39: 74-77Crossref PubMed Scopus (124) Google Scholar), it was suggested that HLA-B27 ligands with C-terminal basic residues may not be relevant for susceptibility to AS. The initial reports that B*2706 and B*2709 did not bind peptides with C-terminal Tyr, a residue that is accepted by disease-associated subtypes B*2705, B*2702, and B*2704, suggested that putative arthritogenic peptides might carry this motif (10Fiorillo M.T. Meadows L. D'Amato M. Shabanowitz J. Hunt D.F. Apella E. Sorrentino R. Eur. J. Immunol. 1997; 27: 368-373Crossref PubMed Scopus (98) Google Scholar, 31Garcia F. Marina A. Lopez de Castro J.A. Tissue Antigens. 1997; 49: 215-221Crossref PubMed Scopus (62) Google Scholar). This view was challenged by the finding that the AS-associated subtype B*2707 failed to show a C-terminal Tyr motif upon pool sequencing (32Tieng V. Dulphy N. Boisgérault F. Tamouza R. Charron D. Toubert A. Immunogenetics. 1997; 47: 103-105Crossref PubMed Scopus (28) Google Scholar). Failure to bind peptides with C-terminal Tyr was recently confirmed for B*2706 (33Sesma L. Montserrat V. Lamas J.R. Marina A. Vazquez J. Lopez de Castro J.A. J. Biol. Chem. 2002; 277: 16744-16749Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar) and, in the present study, for B*2709, but several novel aspects were revealed by our results now. First, although B*2709 specificity is highly restricted to peptides with C-terminal aliphatic or Phe residues two peptides with C-terminal Arg and Tyr, respectively, were found in the B*2709-bound peptide pool. Although both peptides were much more abundant in B*2705 their amount in B*2709 could be immunologically significant because our MS techniques were less sensitive than CTL, which are known to recognize minimal amounts of peptides presented at the cell surface. Thus, exclusion of peptides with C-terminal basic or Tyr residues by B*2709 is not absolute. Second, some B*2709 ligands with C-terminal aliphatic residues were not found in B*2705 and bound this subtype in vitro with moderate efficiency although B*2705 accepts peptides with these motifs. Because there was no obvious differential features arising from the sequences of B*2709-specific ligands, selective binding of some peptides with C-terminal nonpolar residues to B*2709 may be because of a combination of suboptimal motifs at multiple secondary anchor positions. This would be compatible with binding only if compensated by stronger anchoring of the C-terminal nonpolar residue in the more hydrophobic F pocket of B*2709. Thus, B*2709 polymorphism might indirectly modulate residue usage at secondary anchor positions, although this effect would be less drastic than the effect on C-terminal residue usage, and its precise characterization might require very high numbers of individual peptide sequences. Third, the ratio between cell surface-expressed HLA-B27/peptide complexes and β2-microglobulin-free heavy chains was the same for both subtypes. We have previously shown (29Alvarez I. Martı́ M. Vazquez J. Camafeita E. Ogueta S. Lopez de Castro J.A. J. Biol. Chem. 2001; 276: 48740-48747Abstract Full Text Full Text PDF PubMed Scopus (37) Google Scholar) that modification of this ratio toward increasing the latter species in an HLA-B27 mutant correlated with lower overall affinity for the mutant-bound peptide repertoire. Thus, our results suggest that B*2705 and B*2709 do not differ in the average stability of the B27/peptide complexes expressed at the cell surface. A main issue addressed in this study was to what extent the restrictions in C-terminal residue usage imposed by B*2709 polymorphism altered the peptide repertoire, relative to B*2705. All sequenced B*2705-ligands not found in B*2709 had C-terminal Arg, Lys, or Tyr, indicating that the subset of B*2705-bound peptides with these C-terminal residues is largely absent from B*2709. In our analysis B*2705 shared about 79% of its peptide repertoire with B*2709. This figure is fully consistent with the degree of cross-reaction of alloreactive B*2705-specific CTL with B*2709, reported previously (15Garcia-Peydro M. Marti M. Lopez de Castro J.A. J. Immunol. 1999; 163: 2299-2305PubMed Google Scholar). This suggests that many shared ligands adopt similar conformation and antigenic features when bound to both subtypes. The relevance of our results for the pathogenetic role of HLA-B27 in Spa is obviously dependent on the extent to which B*2709 may determine susceptibility for this group of diseases. Because this subtype has been found with significant frequency only in Sardinia, the strongest evidence against involvement of this allotype in AS comes from the absence of B*2709 AS patients in this population (5D'Amato M. Fiorillo M.T. Carcassi C. Mathieu A. Zuccarelli A. Bitti P.P. Tosi R. Sorrentino R. Eur. J. Immunol. 1995; 25: 3199-3201Crossref PubMed Scopus (186) Google Scholar). That none of the four reported B*2709 individuals with Spa in continental Italy showed typical AS or axial pathology, except for sacroiliitis in one case (7Olivieri I. Ciancio G. Padula A. Gaudiano C. Masciandaro S. Moro L. Durante E. Pozzi S. Ferrara G.B. Arthritis Rheum. 2002; 46: 553-554Crossref PubMed Scopus (25) Google Scholar), strongly supports that B*2709 is weakly or not associated with AS but also suggests that this subtype may influence susceptibility to related forms of arthritis. Without excluding alternative mechanisms (34Allen R.L. Bowness P. McMichael A. Immunogenetics. 1999; 50: 220-227Crossref PubMed Scopus (70) Google Scholar, 35Edwards J.C. Bowness P. Archer J.R. Immunol. Today. 2000; 21: 256-260Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar, 36Colbert R.A. Mol. Med. Today. 2000; 6: 224-230Abstract Full Text Full Text PDF PubMed Scopus (105) Google Scholar), our results are compatible with involvement of some peptide(s) belonging to a limited set of the B*2705-bound repertoire in the pathogenesis of AS, as proposed by the arthritogenic peptide hypothesis (37Benjamin R. Parham P. Immunol. Today. 1990; 11: 137-142Abstract Full Text PDF PubMed Scopus (350) Google Scholar). Because peptides with C-terminal basic residues are not bound to B*2702, our results suggest, in agreement with previous studies (10Fiorillo M.T. Meadows L. D'Amato M. Shabanowitz J. Hunt D.F. Apella E. Sorrentino R. Eur. J. Immunol. 1997; 27: 368-373Crossref PubMed Scopus (98) Google Scholar, 31Garcia F. Marina A. Lopez de Castro J.A. Tissue Antigens. 1997; 49: 215-221Crossref PubMed Scopus (62) Google Scholar, 33Sesma L. Montserrat V. Lamas J.R. Marina A. Vazquez J. Lopez de Castro J.A. J. Biol. Chem. 2002; 277: 16744-16749Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar), that putative AS-related peptide(s) might have C-terminal Tyr. The capacity of B*2709 to bind low amounts of some peptides with this motif might explain the apparent relationship of this subtype with undifferentiated Spa. The apparent contradiction that the AS-associated B*2707 subtype does not bind peptides with C-terminal Tyr, based on sequencing by Edman degradation (32Tieng V. Dulphy N. Boisgérault F. Tamouza R. Charron D. Toubert A. Immunogenetics. 1997; 47: 103-105Crossref PubMed Scopus (28) Google Scholar) might require reassessment using the much more sensitive MS sequencing, to determine whether such peptides might bind B*2707 in small amounts as found here for B*2709. There is an alternative interpretation to the relationship between the B*2705- and B*2709-bound peptide repertoires and the differential association of these subtypes to AS. It is conceivable that a putative arthritogenic peptide might actually bind better to a subtype not associated to AS than to a disease-associated subtype, because thymic deletion of autoreactive T-cells against such peptide would be favored for the subtype capable to present it more efficiently. For B*2705 and B*2709, this possibility was suggested by a previous study showing that a synthetic peptide derived from a self-protein that elicited CTL responses in B*2705-positive AS patients better than on healthy individuals actually bound better B*2709 than B*2705 (38Fiorillo M.T. Maragno M. Butler R. Dupuis M.L. Sorrentino R. J. Clin. Invest. 2000; 106: 47-53Crossref PubMed Scopus (160) Google Scholar). According to this view, putative arthritogenic peptides should be among those with C-terminal nonpolar residues that are selectively or predominantly presented by B*2709, such as those found in this study. Discerning between both alternatives requires further research, but our results may help to focus on the limited subsets of HLA-B27-bound peptides that are not overlapping among subtypes differentially associated to AS. We thank Rosa Sorrentino (University La Sapienza, Roma, Italy) for the gift of B*2709 cDNA and Samuel Ogueta for technical assistance in MS. We also thank Dietmar Waidelich (Proteomics Support, Applied Biosystems, Langen, Germany) for MALDI-TOF/TOF sequencing." @default.
• W2034921189 created "2016-06-24" @default.
• W2034921189 creator A5006113461 @default.
• W2034921189 creator A5031783787 @default.
• W2034921189 creator A5040823144 @default.
• W2034921189 creator A5048381673 @default.
• W2034921189 creator A5052132438 @default.
• W2034921189 creator A5081217694 @default.
• W2034921189 date "2002-08-01" @default.
• W2034921189 modified "2023-10-12" @default.
• W2034921189 title "Differential Association of HLA-B*2705 and B*2709 to Ankylosing Spondylitis Correlates with Limited Peptide Subsets but Not with Altered Cell Surface Stability" @default.
• W2034921189 cites W1521491171 @default.
• W2034921189 cites W1528487587 @default.
• W2034921189 cites W1666172410 @default.
• W2034921189 cites W1970077833 @default.
• W2034921189 cites W1974320893 @default.
• W2034921189 cites W1974823499 @default.
• W2034921189 cites W1984895073 @default.
• W2034921189 cites W1999020288 @default.
• W2034921189 cites W2001596381 @default.
• W2034921189 cites W2007318918 @default.
• W2034921189 cites W2007706464 @default.
• W2034921189 cites W2017242640 @default.
• W2034921189 cites W2018705716 @default.
• W2034921189 cites W2026970642 @default.
• W2034921189 cites W2034298592 @default.
• W2034921189 cites W2035967684 @default.
• W2034921189 cites W2046005361 @default.
• W2034921189 cites W2051172084 @default.
• W2034921189 cites W2058722206 @default.
• W2034921189 cites W2067001395 @default.
• W2034921189 cites W2070662767 @default.
• W2034921189 cites W2076370934 @default.
• W2034921189 cites W2078337251 @default.
• W2034921189 cites W2078893421 @default.
• W2034921189 cites W2082173837 @default.
• W2034921189 cites W2088355124 @default.
• W2034921189 cites W2094109363 @default.
• W2034921189 cites W2118376550 @default.
• W2034921189 cites W2157000149 @default.
• W2034921189 cites W2167459719 @default.
• W2034921189 cites W2168931952 @default.
• W2034921189 cites W2170924043 @default.
• W2034921189 doi "https://doi.org/10.1074/jbc.m204155200" @default.
• W2034921189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12042320" @default.
• W2034921189 hasPublicationYear "2002" @default.
• W2034921189 type Work @default.
• W2034921189 sameAs 2034921189 @default.
• W2034921189 citedByCount "79" @default.
• W2034921189 countsByYear W20349211892012 @default.
• W2034921189 countsByYear W20349211892013 @default.
• W2034921189 countsByYear W20349211892014 @default.
• W2034921189 countsByYear W20349211892015 @default.
• W2034921189 countsByYear W20349211892016 @default.
• W2034921189 countsByYear W20349211892019 @default.
• W2034921189 countsByYear W20349211892022 @default.
• W2034921189 countsByYear W20349211892023 @default.
• W2034921189 crossrefType "journal-article" @default.
• W2034921189 hasAuthorship W2034921189A5006113461 @default.
• W2034921189 hasAuthorship W2034921189A5031783787 @default.
• W2034921189 hasAuthorship W2034921189A5040823144 @default.
• W2034921189 hasAuthorship W2034921189A5048381673 @default.
• W2034921189 hasAuthorship W2034921189A5052132438 @default.
• W2034921189 hasAuthorship W2034921189A5081217694 @default.
• W2034921189 hasBestOaLocation W20349211891 @default.
• W2034921189 hasConcept C147483822 @default.
• W2034921189 hasConcept C188280979 @default.
• W2034921189 hasConcept C203014093 @default.
• W2034921189 hasConcept C2777402515 @default.
• W2034921189 hasConcept C2778091532 @default.
• W2034921189 hasConcept C41007239 @default.
• W2034921189 hasConcept C71924100 @default.
• W2034921189 hasConceptScore W2034921189C147483822 @default.
• W2034921189 hasConceptScore W2034921189C188280979 @default.
• W2034921189 hasConceptScore W2034921189C203014093 @default.
• W2034921189 hasConceptScore W2034921189C2777402515 @default.
• W2034921189 hasConceptScore W2034921189C2778091532 @default.
• W2034921189 hasConceptScore W2034921189C41007239 @default.
• W2034921189 hasConceptScore W2034921189C71924100 @default.
• W2034921189 hasIssue "32" @default.
• W2034921189 hasLocation W20349211891 @default.
• W2034921189 hasOpenAccess W2034921189 @default.
• W2034921189 hasPrimaryLocation W20349211891 @default.
• W2034921189 hasRelatedWork W1604141016 @default.
• W2034921189 hasRelatedWork W2037834355 @default.
• W2034921189 hasRelatedWork W2054946938 @default.
• W2034921189 hasRelatedWork W2132385515 @default.
• W2034921189 hasRelatedWork W2244128811 @default.
• W2034921189 hasRelatedWork W2391471515 @default.
• W2034921189 hasRelatedWork W2508588692 @default.
• W2034921189 hasRelatedWork W2782161018 @default.
• W2034921189 hasRelatedWork W2492403483 @default.
• W2034921189 hasRelatedWork W2739685159 @default.
• W2034921189 hasVolume "277" @default.
• W2034921189 isParatext "false" @default.
• W2034921189 isRetracted "false" @default.
• W2034921189 magId "2034921189" @default.
• W2034921189 workType "article" @default.